PPH (PHARMA ETF) SELL TILL 66Time to unload strategically pharma stocks for 6-12 months.
66 first target
Key stats
About VanEck Pharmaceutical ETF
Expense ratio
0.36%
Home page
Inception date
Dec 20, 2011
ISIN
US92189F6925
PPH provides exposure to the largest, US-listed multinational pharmaceutical giants in the world. The fund holds just 25 securities, including big weights in household names. Like the underlying pharmaceutical market, PPH is top heavy and has to reweight its big holdings to accommodate RIC diversification requirements, capping a single issuer to 20%. Still, it captures the space well, even after excluding Asia entirely. Overall, PPH is a great option for investors seeking exposure to big, multinational pharma companies. The index is reviewed on a semi-annual basis.
Classification
What's in the fund
Exposure type
Health Technology
Distribution Services
Stock breakdown by region
Pharma bull divergence -COVIDNormally when we see a such massive drops in equity, the on balance volume also trends down.
OBV is reaching a 2-year high, as we have dropped over 30%.
This divergence suggests pharmaceuticals could outperform as the market starts consolidating.
----
Regarding the volatility due to Medicare for
Pharma ETF - bull divergence!As the PPH dropped 15% below the 200sma, OBV barely moved lower compared to the drop. (Between purple vertical lines). This is considered a Bullish Divergence .
Now with a strong pullback, we are half way to reach past highs; but this time with an OBV we have not yet seen since Feb, 2018.
Ready
$PPH 'right to try'I expect big pharma to love the opportunity to get the chance to trial drugs on humans using informed consent as djt just signed the 'right to try act'.
Should be good for them and the terminally ill tbh
GL HF
xoxo
snoop
See all ideas